Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2026
2025
2024
2023
2022
2021

Jun 25 2023

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

Read More +

May 12 2023

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

Read More +

May 3 2023

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

Read More +

Apr 19 2023

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

Read More +

Mar 20 2023

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

Read More +

Feb 2 2023

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

Read More +

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 16 of 16

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2026 - MoonLake Immunotherapeutics

Privacy Policy